About
News
Calendar
Education & Training
Careers
How to Help
Contact Us
My Dana-Farber
Español
Find a Doctor
Get Directions
For Physicians
Make a Gift
Adult Care
Treatment and Care
Treatment Centers and Clinical Services
Care Team
Patient And Family Support
Care Quality and Patient Safety
Patient Stories
For Adult Cancer Survivors
Browse by Cancer Type
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
New Patient Guide
Planning a Visit
Driving Directions
Parking at Dana-Farber
Maps of Dana-Farber
Preparing for Your First Visit
How to Prepare
Talking to Your Doctor
Financial and Legal Matters
Insurance and Financial Assistance
Your Role as Patient
Ethics Consultation
Health Care Proxy
Special Assistance
Interpreters
Patient Navigators
Disability Services
Patient Safety and Advocacy
Safety Information
Patient Relations
Adult Patient and Family Advisory Council
Legislative Action Network
Amenities and Resources
Concierge Services
Appointments & Second Opinions
New Patient?
For appointments or second opinions:
Adults:
(877) 442-DFCI (442-3324)
Children:
(888) PEDI-ONC (733-4662)
or complete the
Appointment Request Form
Online Specialty Consultations
International Patients
Referring Physician?
To refer an adult patient:
(877) 441-DFCI (441-3324)
To refer a pediatric patient:
(888) PEDI-ONC (733-4662)
or complete the
Patient Referral Form
Pediatric Care
Treatment and Care
Pediatric Treatment Centers and Clinical Services
Care Team
Patient And Family Support
Care Quality and Patient Safety
Patient Stories
For Survivors of Childhood Cancer
Browse by Cancer Type
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
New Patient Guide
Planning a Visit
Driving Directions
Parking at Dana-Farber
Maps of Dana-Farber
Preparing for Your First Visit
How to Prepare
Talking to Your Child's Doctor
Financial and Legal Matters
Insurance and Financial Assistance
Your Role as Patient
Ethics Consultation
Health Care Proxy
Special Assistance
Interpreters
Disability Services
Patient Safety and Advocacy
Safety Information
Patient Relations
Legislative Action Network
Pediatric Patient and Family Advisory Council
Amenities and Resources
Concierge Services
Appointments & Second Opinions
New Patient?
For appointments or second opinions:
Adults:
(877) 442-DFCI (442-3324)
Children:
(888) PEDI-ONC (733-4662)
or complete the
Appointment Request Form
Your Child's Care Team
For International Patients
Referring Physician?
To refer an adult patient:
(877) 441-DFCI (441-3324)
To refer a pediatric patient:
(888) PEDI-ONC (733-4662)
or complete the
Patient Referral Form
Research
Clinical Trials
Research Advances
Featured Research
Departments and Centers
Integrative Research Centers
Core Facilities
Research Administration
Technology Transfer
Find a Researcher
Health Library
Blog
Home
Research
Clinical Trials
Clinical Trials by Diagnosis
GYN: Cervical Cancer Clinical Trials
Showing 1-5 of 5 items
1.
Image-Guided Gynecologic Brachytherapy
Standard therapy for gynecologic cancers involves the use of brachytherapy, also called internal radiation therapy or implant radiation. The treatment being studied consists of standard brachytherapy with the additional use of MRI to guide the insertion of radioactive applicators. The purpose of the study is to find out whether MRI-guided brachytherapy is practical and beneficial when compared to the standard CT-guided brachytherapy placement. The investigators are hoping that this MRI procedure will decrease the risk of giving too high a radiation dose to the bladder or bowel.
Diagnoses:
GYN: Cervical Cancer
,
GYN: Endometrial/Uterine Cancer
Status:
Recruiting
2.
PET-CT vs. Integrated MR-PET Scanning of GYN Cancers
This research study is an imaging pilot study. Imaging pilot studies explore the potential benefit of one imaging approach compared to another clinically accepted approach. Such studies serve to understand how feasible an approach may be and whether it is worth pursuing in formal and larger clinical trials. Researchers of this study believe that simultaneous Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) imaging will offer additional imaging information to improve cancer detection. MRI and PET are two tests that allow us to take pictures of the body and "look inside" the body without surgery. The MRI scanner uses a powerful magnet to make a picture of the body. The PET scanner makes pictures by using special dyes that "light up" inside the body. PET scans use radiation, similar to the radiation in a standard x-ray. We routinely use both tests to diagnose various types of cancer. As of now, the combination of PET and computed tomography (CT) has been considered a standard of care imaging approach for various cancers. Until recently, MRI and PET tests were done separately. Now there is a new type of test called MR-PET that combines both MRI and PET test results. This scanner uses both MRI and PET tests at the same time. We would like to find out if the MR-PET scanner can produce better and clearer images (pictures) of tumors and information about them inside of the body. This new MR-PET scanner is approved by the US FDA. However, some of the computer programs that tell the machine how to acquire and combine the test results are new and experimental. Experimental means that some of the computer programs are not approved by the FDA. This means that they can only be used in research studies. The MR-PET scanner has been previously used in a few human participants.
Diagnoses:
GYN: Endometrial/Uterine Cancer
,
GYN: Cervical Cancer
,
GYN: Ovarian, Fallopian, Peritoneal Cancer
Status:
Recruiting
3.
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel and Carboplatin With or Without Bevacizumab in Patients With Solid Tumors
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0980 administered with paclitaxel and carboplatin with or without bevacizumab to patients with locally advanced or metastatic solid tumors.
Diagnoses:
Lung Cancer
,
GYN: Endometrial/Uterine Cancer
,
GYN: Ovarian, Fallopian, Peritoneal Cancer
,
GYN: Cervical Cancer
Status:
Recruiting
4.
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
This open-label, multi-center study will assess the efficacy and safety of vemurafenib in patients with BRAF V600 mutation-positive cancers (solid tumors and multiple myeloma, except melanoma and papillary thyroid cancer) and for whom vemurafenib is deemed the best treatment option in the opinion of the investigator. Patients will receive twice daily oral doses of 960 mg vemurafenib until disease progression, unacceptable toxicity, or withdrawal of consent.
Diagnoses:
Gastrointestinal Malignancies
,
GYN: Cervical Cancer
,
GYN: Ovarian, Fallopian, Peritoneal Cancer
,
GYN: Endometrial/Uterine Cancer
Status:
Recruiting
5.
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumor
To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies resistant to standard therapy.
Diagnoses:
GYN: Ovarian, Fallopian, Peritoneal Cancer
,
GYN: Endometrial/Uterine Cancer
,
GYN: Cervical Cancer
Status:
Recruiting
Showing 1-5 of 5 items
Email
Print
Share
Text
Highlight Glossary Terms